Stock·NASDAQ·Healthcare
Neogen Corp. (NEOG)
- Market cap
- $2.58B
- Dividend yield
- 0.00%
- Street target
- $14.00median of 4 analysts
- 52-week range
- $5.37 $14.26
The short version
Where NEOG stands today, in four lines, and what CleaRank Financial AI makes of it.
NEOG at a glance
Neogen Corp. (NEOG): Hold, 58/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($10.23 and $12.16).
- Insiders Insiders bought $729K and made no open-market sales over the last 18 months.
Figures as of October 17, 2026.
CleaRank Financial AI
NEOG, or Neogen Corp., gets a Hold from CleaRank with a model score of 58/100.
Trend is the factor that lifts the score most, since the price is 15.39% above its 200-day average and the 50-day average is 18.78% above the 200-day. Valuation pulls hardest in the other direction, because the company has no meaningful P/E after losing money. The 50-day average is $12.16 and the 200-day is $10.23. Across the past year, the price climbed 99.16%.
Only on CleaRank
Figures we compute ourselves from NEOG's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $11.81 is 2.9% below the 50-day simple moving average of $12.16.Price above its 200-day average ›
The price is 15.4% above the 200-day simple moving average of $10.23.50-day average above the 200-day ›
The 50-day average ($12.16) is 18.8% above the 200-day average ($10.23), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 72% of its 52-week range, between $5.37 and $14.26.
NEOG share price
Pick a period: each tab shows how far NEOG has moved over it, to the last close.
Today's trading
Where NEOG sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/2P/S below the sector median ›
The price-to-sales ratio of 3.03 is 10.9% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-56.1M on revenue of $884.0M, a net margin of -6.3%.
Key statistics
The headline figures for NEOG.
As of October 17, 2026, NEOG trades at $11.81, with a market value of $2.58B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of NEOG's valuation, growth and risks.
Neogen Corp. (NEOG) carries no meaningful P/E, because the company lost money over the last 12 months. On sales, its P/S of 3.03 sits 10.9% below the sector median of 3.4. Its market capitalisation is $2.6B.
NEOG is losing money: its net margin is -6.35% and its operating margin is -0.81%. Return on equity of -2.67% trails the sector median of 7.3%. Revenue rose 6.50% in the latest year, leaving it 1.6 percentage points behind the Healthcare median of 8.1%. Debt-to-equity stands at 0.37.
NEOG reported $0.08 a share in its latest earnings report, dated October 6, 2026, compared with a $0.05 estimate. That result beat the estimate by 60.00%, yet the stock fell 2.34% in the following session.
NEOG has topped its EPS estimate in all 2 of its recent reports, but the share price dropped in the first session after each of those 2 beats. Analysts expect EPS of $0.28 this fiscal year and $0.38 next, so the current year is forecast to shrink by 12.5%.
NEOG is a stock where day-to-day swings matter most. On an average session it moves 3.16%. The price also sits 17.18% below its 52-week high of $14.26.
NEOG against the Healthcare sector
How NEOG compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, NEOG trades at 3.03x, -11% versus the sector average of 3.40x.
Return vs XLV: Since May 6, 2025, NEOG has gained 115.1% against a gain of 31.6% for XLV.
Performance against XLV
NEOG and the Healthcare sector fund over the same days.
Revenue and earnings
How much NEOG sells, and how much of it becomes profit.
Revenue growth: Revenue fell 2.7% in FY2026 to $870M, from $895M a year earlier.
Profit margin: The net margin was -0.9% in FY2026, up from -122.1% the year before.
Loss-making: NEOG lost $7.9M in FY2026.
Earnings reality check
Did NEOG beat what analysts expected, and how did the stock react?
Earnings record: NEOG beat the analyst estimate in 2 of the last 2 quarters.
Market reaction: The stock fell in the first session after 2 of those 2 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 6, 2026after close | $0.05 | $0.08 | +60.00% | -2.34% | -1.92% |
| Apr 9, 2026after close | $0.05 | $0.09 | +80.00% | -6.18% | -7.97% |
As of October 17, 2026, NEOG has beaten the analyst EPS estimate in 2 of its last 2 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on October 6, 2026, came in 60.00% above the estimate and the stock moved -2.34% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 44.7, in neutral territory.RSI above 50 ›
An RSI of 44.7 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of NEOG
The score, the reasoning behind it, and what could move the price next.
NEOG is trading between its two moving averages. At $11.81, the stock sits 15.39% above its 200-day average of $10.23 but 2.86% below its 50-day average of $12.16. With the price at 72% of its 52-week range, it is 17.18% below the 52-week high of $14.26.
Recent weakness sits inside a firmer longer-term picture. Over the past month the price slid 5.90%, but it climbed 15.00% across three months and 99.16% across the past year. The 14-day RSI sits at 44.7, in the neutral zone, and the MACD line is negative.
Analyst upgrade ›
Piper Sandler upgraded it to Overweight from Neutral on August 26, 2026.
Source: Analyst action, Piper Sandler, August 26, 2026Rating reaffirmed ›
Guggenheim kept its Buy rating on September 30, 2026.
Source: Analyst action, Guggenheim, September 30, 2026
Earnings beat ›
The October 6, 2026 report beat the EPS estimate by 60.00%, and the share price fell 2.34% in the first session after it.
Source: Earnings report, October 6, 2026
- The two levels closest to NEOG's price are the 50-day SMA at $12.16, which sits above it, and the 200-day SMA at $10.23, which sits below.
- The 14-day RSI stands at 44.7, which is neutral, and the MACD line is negative. Readings above 70 or below 30 point to stretched momentum.
- The share price dropped 2.34% in the first session after the October 6, 2026 report, even though NEOG beat estimates in 2 of the last 2 reports.
NEOG has a mixed trend: it sits above its 200-day average of $10.23 but below its 50-day average of $12.16. Should the price close above the 50-day, both signals would point up; a close below the 200-day would point both down. For now the price is wedged between the 200-day SMA ($10.23) below and the 50-day SMA ($12.16) above.
Technical indicators
Momentum and trend for NEOG, from its daily closes.
As of October 17, 2026, with NEOG at $11.81, its 14-day RSI is 44.7 (neutral territory), its 50-day simple moving average is $12.16 and its 200-day is $10.23.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What NEOG moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, NEOG's 1-year correlation of daily returns is +0.07 with S&P 500 (SPY), +0.07 with Nasdaq 100 (QQQ), +0.11 with Bitcoin (BTC) and -0.05 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
3 of 4 analysts rate it a buy or strong buy, 1 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $14.00 is 18.5% above the price.More buy ratings than three months ago ›
3 of 4 rate it a buy now, against 2 of 4 three months ago.
NEOG Wall Street View
12-month price targets
The price, $11.81, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 30, 2026 | Guggenheim | Maintains | Buy |
| Aug 26, 2026 | Piper Sandler | Upgrade | Overweight |
| Aug 3, 2026 | Piper Sandler | Reiterates | Neutral |
As of October 17, 2026, 4 Wall Street analysts cover NEOG: 3 rate it a buy or strong buy, 1 a hold and 0 a sell or strong sell. Their 12-month price targets range from $14.00 to $14.00, with a median of $14.00, 18.5% above the price of $11.81.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
NEOG trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
NEOG moves about 3.2% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much NEOG tends to move, against the market and on its own.
The long record
NEOG's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
0/4Average daily move under 2% ›
The price has moved 3.16% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 90.9%, from April 2021 to April 2025; the price is still 75.5% below that peak.Most 1-year holds ended higher ›
51% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $5,971.07, against $42,055 in the S&P 500 (SPY).
NEOG Drawdowns & Recovery
As of October 17, 2026, NEOG's worst peak-to-trough fall over the last 10 years with dividends reinvested was -90.9% (April 2021 to April 2025); it is still 75.5% below that peak, and 51% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into NEOG in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: NEOG trailed the S&P 500 over this period: $5,971.07 against $42,055.
A $10,000 investment in NEOG in October 2016 would be worth about $5,971 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to NEOG, and which have not.
Strongest month, November: an average of +7.66%, up in 9 of 10 years.
Weakest month, October: an average of -7.56%, up in 2 of 9 years.
This month, October: has averaged -7.56%, up in 2 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, NEOG's strongest calendar month has been November (average +7.66%, up in 9 of 10 years) and its weakest October (average -7.56%, up in 2 of 9 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in NEOG, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in NEOG today could grow to about $10,179 by 2036 in the base case, with a 90th-percentile outcome near $57,591 and a 10th-percentile outcome around $1,799. Projections are statistical simulations, not guarantees.
NEOG Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $11.89 for NEOG by 2030 in the base case, from $11.81 today (1.0x over 4 years). The 10th-percentile path ends near $3.97. These are outcomes of a Monte Carlo simulation run on NEOG's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $6.84 | $11.83 | $20.47 | |
| 2028 | $5.46 | $11.85 | $25.73 | |
| 2029 | $4.60 | $11.87 | $30.68 | |
| 2030 | $3.97 | $11.89 | $35.59 | |
| 2031 | $3.50 | $11.92 | $40.58 |
Method: a lognormal simulation of NEOG's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
NEOG insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $729K on the open market.
As of October 17, 2026, NEOG insiders reported no open-market sales and 14 open-market purchases worth $729K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 14, 2026 | Mikheal Nassif
Chief Executive Officer
|
Grant | 141.6K | $1.7M |
| Aug 14, 2026 | Tamara A Ranalli
Officer
|
Grant | 25.8K | $300.0K |
| Aug 14, 2026 | Richard Bryan Riggsbee
Chief Financial Officer
|
Grant | 51.5K | $600.0K |
| Aug 14, 2026 | Jennifer Evans Stacey
Officer
|
Grant | 38.6K | $450.0K |
| Aug 4, 2026 | Mikheal Nassif
Chief Executive Officer
|
Buy | 370 | $4.4K |
| May 18, 2026 | Amy M Rocklin
Former
|
Option | 35.2K | $326.9K |
| May 4, 2026 | John Patrick Moylan
Officer
|
Option | 4.6K | $43.4K |
| May 1, 2026 | Jennifer Evans Stacey
Officer
|
Grant | 39.3K | $375.0K |
| Feb 17, 2026 | Mikheal Nassif
Chief Executive Officer
|
Buy | 23 | $252 |
| Feb 2, 2026 | Mikheal Nassif
Chief Executive Officer
|
Buy | 49 | $486 |
| Jan 16, 2026 | Mikheal Nassif
Chief Executive Officer
|
Buy | 137 | $1.3K |
| Jan 7, 2026 | Tamara A Ranalli
Officer
|
Grant | 50.8K | $375.0K |
| Jan 7, 2026 | Tamara A Ranalli
Officer
|
Grant | 101.6K | $750.0K |
| Dec 1, 2025 | David Hartman Naemura
Former
|
Option | 12.9K | $77.2K |
| Nov 3, 2025 | Mikheal Nassif
Chief Executive Officer
|
Buy | 177 | $1.1K |
| Nov 3, 2025 | Richard Bryan Riggsbee
Chief Financial Officer
|
Grant | 178.9K | $1.1M |
| Oct 27, 2025 | John Edward Adent
Former
|
Option | 38.8K | $239.9K |
| Oct 27, 2025 | William T Boehm
Director
|
Option | 3.6K | $21.6K |
| Oct 27, 2025 | James C. Borel
Director
|
Option | 1.8K | $11.0K |
| Oct 27, 2025 | James C. Borel
Director
|
Option | 2.0K | $12.5K |
| Oct 27, 2025 | Jeffrey D Capello
Director
|
Option | 1.8K | $11.0K |
| Oct 27, 2025 | Jeffrey D Capello
Director
|
Option | 2.0K | $12.5K |
| Oct 27, 2025 | Ronald D Green
Director
|
Option | 1.8K | $11.0K |
| Oct 27, 2025 | Aashima Gupta
Director
|
Option | 1.8K | $11.0K |
| Oct 27, 2025 | Douglas Edward Jones
Former
|
Option | 15.5K | $96.0K |
| Oct 27, 2025 | David Hartman Naemura
Chief Financial Officer
|
Option | 15.5K | $96.0K |
| Oct 27, 2025 | Amy M Rocklin
Officer
|
Option | 9.5K | $58.6K |
| Oct 27, 2025 | Rafael A Rodriguez
Director
|
Option | 1.8K | $11.0K |
| Oct 27, 2025 | James P Tobin
Director
|
Option | 1.8K | $11.0K |
| Oct 27, 2025 | Catherine E Woteki
Director
|
Option | 1.8K | $11.0K |
| Oct 24, 2025 | Avi Pelossof
Director
|
Grant | 19.4K | $120.0K |
| Oct 23, 2025 | Thierry Bernard
Director
|
Grant | 19.8K | $120.0K |
| Oct 23, 2025 | James C. Borel
Director
|
Grant | 19.8K | $120.0K |
| Oct 23, 2025 | Jeffrey D Capello
Director
|
Grant | 19.8K | $120.0K |
| Oct 23, 2025 | Ronald D Green
Director
|
Grant | 19.8K | $120.0K |
| Oct 23, 2025 | Aashima Gupta
Director
|
Grant | 19.8K | $120.0K |
| Oct 23, 2025 | Rafael A Rodriguez
Director
|
Grant | 19.8K | $120.0K |
| Oct 23, 2025 | Andrea F Wainer
Director
|
Grant | 19.8K | $120.0K |
| Oct 23, 2025 | Catherine E Woteki
Director
|
Grant | 19.8K | $120.0K |
| Oct 13, 2025 | John Edward Adent
Former
|
Option | 3.1K | $18.5K |
| Oct 13, 2025 | Douglas Edward Jones
Former
|
Option | 783 | $4.7K |
| Oct 13, 2025 | Amy M Rocklin
Officer
|
Option | 294 | $1.8K |
| Oct 7, 2025 | John Edward Adent
Former
|
Option | 32.9K | $185.4K |
| Oct 7, 2025 | William T Boehm
Director
|
Option | 2.1K | $11.7K |
| Oct 7, 2025 | James C. Borel
Director
|
Option | 2.1K | $11.7K |
| Oct 7, 2025 | Jeffrey D Capello
Director
|
Option | 2.1K | $11.7K |
| Oct 7, 2025 | Ronald D Green
Director
|
Option | 2.1K | $11.7K |
| Oct 7, 2025 | Aashima Gupta
Director
|
Option | 2.1K | $11.7K |
| Oct 7, 2025 | Douglas Edward Jones
Former
|
Option | 12.9K | $72.9K |
| Oct 7, 2025 | Amy M Rocklin
Officer
|
Option | 9.0K | $48.4K |
| Oct 7, 2025 | Rafael A Rodriguez
Director
|
Option | 2.1K | $11.7K |
| Oct 7, 2025 | James P Tobin
Director
|
Option | 2.1K | $11.7K |
| Oct 7, 2025 | Catherine E Woteki
Director
|
Option | 2.1K | $11.7K |
| Aug 18, 2025 | John Edward Adent
Chief Executive Officer
|
Option | 35.7K | $194.0K |
| Aug 18, 2025 | Douglas Edward Jones
Chief Operating Officer
|
Option | 14.3K | $77.6K |
| Aug 18, 2025 | John Patrick Moylan
Officer
|
Option | 2.0K | $10.8K |
| Aug 18, 2025 | David Hartman Naemura
Chief Financial Officer
|
Option | 14.3K | $77.6K |
| Aug 18, 2025 | Amy M Rocklin
Officer
|
Option | 10.3K | $56.1K |
| Aug 15, 2025 | John Patrick Moylan
Officer
|
Grant | 18.4K | $100.0K |
| Aug 15, 2025 | David Hartman Naemura
Chief Financial Officer
|
Grant | 230.2K | $1.3M |
| Aug 15, 2025 | Mikheal Nassif
Chief Executive Officer
|
Grant | 598.5K | $3.3M |
| Aug 15, 2025 | Amy M Rocklin
Officer
|
Grant | 119.7K | $650.0K |
| Jun 2, 2025 | John Patrick Moylan
Officer
|
Grant | 26.4K | $150.0K |
| Jun 2, 2025 | David Hartman Naemura
Chief Financial Officer
|
Grant | 52.7K | $300.0K |
| Jun 2, 2025 | Amy M Rocklin
Officer
|
Grant | 43.6K | $248.0K |
| Jun 2, 2025 | Andrea F Wainer
Director
|
Grant | 6.1K | $34.7K |
| May 12, 2025 | Aashima Gupta
Director
|
Buy | 16.0K | $100.0K |
| May 1, 2025 | John Patrick Moylan
Officer
|
Option | 4.6K | $23.5K |
| Apr 28, 2025 | John Edward Adent
Chief Executive Officer
|
Option | 2.1K | $10.9K |
| Apr 28, 2025 | Douglas Edward Jones
Chief Operating Officer
|
Option | 845 | $4.4K |
| Apr 28, 2025 | Amy M Rocklin
Officer
|
Option | 564 | $2.9K |
| Apr 25, 2025 | Catherine E Woteki
Director
|
Buy | 5.8K | $29.8K |
| Apr 24, 2025 | William T Boehm
Director
|
Buy | 5.0K | $26.2K |
| Apr 24, 2025 | James C. Borel
Director
|
Buy | 30.0K | $149.7K |
| Apr 24, 2025 | James C. Borel
Director
|
Buy | 35.0K | $171.3K |
| Apr 23, 2025 | Amy M Rocklin
Officer
|
Buy | 12.5K | $62.4K |
| Apr 22, 2025 | Jeffrey D Capello
Director
|
Buy | 20.7K | $100.2K |
| Apr 22, 2025 | Rafael A Rodriguez
Director
|
Buy | 7.5K | $34.3K |
| Apr 22, 2025 | James P Tobin
Director
|
Buy | 10.0K | $47.3K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.